MediciNova Inc. Daily Stock Analysis

Daily Stock Analysis, MNOV, MediciNova Inc, priceseries

MediciNova Inc. Daily Stock Analysis
Stock Information
Open
2.32
Close
2.30
High
2.36
Low
2.30
Previous Close
2.40
Daily Price Gain
-0.10
YTD High
2.86
YTD High Date
Jan 4, 2022
YTD Low
2.13
YTD Low Date
Jan 24, 2022
YTD Price Change
-0.48
YTD Gain
-17.27%
52 Week High
10.81
52 Week High Date
Mar 10, 2021
52 Week Low
2.13
52 Week Low Date
Jan 24, 2022
52 Week Price Change
-3.06
52 Week Gain
-57.09%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Aug 18. 2017
4.97
Sep 5. 2017
5.30
11 Trading Days
6.55%
Link
LONG
Sep 20. 2017
5.66
Oct 5. 2017
6.30
11 Trading Days
11.34%
Link
LONG
Oct 25. 2017
6.53
Oct 26. 2017
7.19
1 Trading Days
10.11%
Link
LONG
Jan 25. 2018
7.68
Feb 8. 2018
8.94
10 Trading Days
16.46%
Link
LONG
Feb 13. 2018
9.51
Feb 27. 2018
10.55
9 Trading Days
10.94%
Link
LONG
Mar 1. 2018
10.81
Mar 19. 2018
12.66
12 Trading Days
17.11%
Link
LONG
Aug 23. 2018
9.73
Sep 6. 2018
11.36
9 Trading Days
16.70%
Link
LONG
Apr 22. 2019
9.94
May 20. 2019
10.91
20 Trading Days
9.76%
Link
LONG
Apr 8. 2020
4.41
Apr 21. 2020
5.07
8 Trading Days
15.02%
Link
LONG
Mar 9. 2021
5.68
Mar 12. 2021
6.19
3 Trading Days
8.98%
Link
LONG
Aug 24. 2021
3.69
Sep 14. 2021
3.89
14 Trading Days
5.32%
Link
Company Information
Stock Symbol
MNOV
Exchange
NasdaqGM
Company URL
http://www.medicinova.com
Company Phone
858-373-1500
CEO
Yuichi Iwaki
Headquarters
California
Business Address
4275 EXECUTIVE SQUARE, SUITE 650, LA JOLLA, CA 92037
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001226616
About

MediciNova, Inc. operates as a biopharmaceutical company with interest in acquiring and developing novel, small molecule therapeutics for the treatment of serious diseases for the treatment of diseases with unmet medical need with a specific focus on the U.S. market. The company's development pipeline consists of product development programs which have been in clinical development for the treatment of acute exacerbations of asthma, chronic obstructive pulmonary disease exacerbations, multiple sclerosis and other neurologic conditions, asthma, interstitial cystitis, solid tumor cancers, generalized anxiety disorder, preterm labor and two preclinical-stage compounds for the treatment of thrombotic disorders. MediciNova was founded by Yuichi Iwaki on September 26, 2000 and is headquartered in San Diego, CA.

Description

MediciNova, Inc., a biopharmaceutical company, focuses on acquiring and developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company's product candidate includes MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for the treatment of neurological disorders, including primary and secondary progressive multiple sclerosis; amyotrophic lateral sclerosis; and substance dependence and addiction, including methamphetamine, opioid, and alcohol dependence. Its product pipeline also comprises MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, such as nonalcoholic steatohepatitis, idiopathic pulmonary fibrosis, and other fibrotic diseases; MN-221 (bedoradrine), a ß2-adrenergic receptor agonist for the treatment of acute exacerbation of asthma; and MN-029 (denibulin), a tubulin binding agent to treat solid tumor cancers. The company was founded in 2000 and is headquartered in La Jolla, California.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading